EschbachJ.W., EgrieJ.C., DowningM.R., BrowneJ.K., AdamsonJ.M.Correction of the anemia of end-stage renal disease with recombinant human erythropoietin.N Engl J Med1987; 316(2): 73–8.
2.
WinearlsC.G., PippardM.J., DowningM.R., OliverD.O., ReidC., CotesP.M.Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic haemodialysis.Lancet1986; 2: 1175–7.
3.
EschbachJ.W., AbdulhadiM.H., BrowneJ.K.Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of the phase III multicenter clinical trial.Ann Intern Med1989; 111: 992–1000.
4.
EschbachJ.W., AdamsonJ.W.Recombinant human erythropoietin implications for nephrology.Am J Kidney Dis1988; 11: 203–9.
5.
BesaradA.Recombinanthumanerythropoietin: physiology, pathophysiology of anemia in renal failure, and economic aspects related to dosing.Am J Nephrol1990; 10(Suppl 2): 2–6.
6.
PoweN.R., GriffithsR.I., GreenJ.W.Early dosing practices and effectiveness of recombinant human erythropoietin.Kidney Int1993; 43: 1125–33.
7.
HumphriesJ.E.Anemia of renal failure.Med Clin North Am1992; 76(3): 711–25.
8.
ZacheeP., ChewS.L., DaelemansR., LinsR.L.Erythro poietin resistance due to vitamin B12 deficiency. Case Report.Am J Nephrol1992; 12: 188–91.
9.
ChandraM., ClemonsG.K., McVicarM.Serum erythropoietin levels and hematocrit in end-stage renal disease: influence of the mode of dialysis.Am J Kidney Dis1988; XII(3): 208–13.
